InsiderClue
Insiders · Profile

Shah Gaurav

CEO at ROCKET PHARMACEUTICALS. Filing since 1 Mar 2019. CIK 0001725922

Company
Date
Role
Action
Shares
Amount
Of holding
RCKT ROCKET PHARMACEUTICALS, INC.
18 Aug 2026
CEO
Sold at will
2,293
$7.75K
0.2%
RCKT ROCKET PHARMACEUTICALS, INC.
13 Aug 2026
CEO
Sold at will
2,837
$9.59K
0.3%
RCKT ROCKET PHARMACEUTICALS, INC.
21 May 2026
CEO
Sold at will
55,684
$171.84K
5.0%
RCKT ROCKET PHARMACEUTICALS, INC.
19 May 2026
CEO
Sold at will
2,409
$7.26K
0.2%
RCKT ROCKET PHARMACEUTICALS, INC.
13 May 2026
CEO
Sold at will
2,728
$9.84K
0.3%
RCKT ROCKET PHARMACEUTICALS, INC.
18 Feb 2026
CEO
Sold at will
5,990
$19.99K
0.6%
RCKT ROCKET PHARMACEUTICALS, INC.
13 Feb 2026
CEO
Sold at will
12,279
$40.67K
1.2%
RCKT ROCKET PHARMACEUTICALS, INC.
18 Nov 2025
CEO
Sold at will
6,276
$18.72K
0.8%
RCKT ROCKET PHARMACEUTICALS, INC.
20 May 2025
CEO
Sold at will
2,253
$14.52K
0.3%
RCKT ROCKET PHARMACEUTICALS, INC.
16 May 2025
CEO
Sold at will
3,621
$23.64K
0.5%
RCKT ROCKET PHARMACEUTICALS, INC.
10 Apr 2025
CEO
Bought
20,000
$101.60K
2.6%
RCKT ROCKET PHARMACEUTICALS, INC.
21 Feb 2025
CEO
Sold at will
16,303
$172.49K
2.1%
RCKT ROCKET PHARMACEUTICALS, INC.
21 Nov 2024
CEO
Sold at will
11,091
$144.78K
1.5%
RCKT ROCKET PHARMACEUTICALS, INC.
16 Aug 2024
CEO
Sold at will
9,650
$178.56K
1.3%
RCKT ROCKET PHARMACEUTICALS, INC.
16 May 2024
CEO
Sold at will
9,790
$228.60K
1.3%
RCKT ROCKET PHARMACEUTICALS, INC.
16 Feb 2024
CEO
Sold at will
20,272
$604.88K
3.5%
RCKT ROCKET PHARMACEUTICALS, INC.
17 Aug 2023
CEO
Sold at will
4,767
$73.75K
0.9%
RCKT ROCKET PHARMACEUTICALS, INC.
17 May 2023
CEO
Sold at will
4,122
$88.11K
0.8%
RCKT ROCKET PHARMACEUTICALS, INC.
17 Feb 2023
CEO
Sold, plan not stated
12,194
$232.42K
2.2%
RCKT ROCKET PHARMACEUTICALS, INC.
7 Feb 2022
CEO
Bought
22,000
$381.51K
4.4%
RCKT ROCKET PHARMACEUTICALS, INC.
5 Mar 2019
See Remarks
Sold, plan not stated
25,000
$422.50K
3.5%
RCKT ROCKET PHARMACEUTICALS, INC.
4 Mar 2019
See Remarks
Sold, plan not stated
24,900
$430.27K
3.4%
RCKT ROCKET PHARMACEUTICALS, INC.
1 Mar 2019
See Remarks
Sold, plan not stated
25,000
$433.50K
3.3%
23 decisions on file.